Recent Trends in Pharmaceutical Technology & Industries
Volume 5, Issue 2 - 2023, Pg. No. 1-6
Peer Reviewed & Open Access Journal

Review Article

Exosomes as Drug Delivery Vehicles: Harnessing the Potential of Extracellular Vesicles

Purnima TK,[1] Kavitha Reddy[2]

[1,2]Care College of Pharmacy, Andhra Pradesh, India.

I N F O

Coresponding Author:
Purnima TK, Care College of Pharmacy, Andhra Pradesh, India.
E-mail Id:
purnimatk14@gmail.com
How to cite this article:
Purnima TK, Reddy K. Exosomes as Drug Delivery Vehicles: Harnessing the Potential of Extracellular Vesicles. *Rec Trends Pharm Tech Ind* 2023; 5(2): 1-6.

Date of Submission: 2023-07-15
Date of Acceptance: 2023-08-27

A B S T R A C T

Exosomes, small extracellular vesicles derived from various cell types, have emerged as promising candidates for drug delivery due to their unique biological properties. This review provides an in-depth analysis of the current state of research on exosomes as drug delivery vehicles, exploring their biogenesis, composition, and potential applications in therapeutic interventions. The focus is on harnessing the inherent advantages of exosomes, such as their natural targeting ability and low immunogenicity, to enhance drug delivery precision and efficacy.

Keywords: Exosomes, cellular origin, dynamic cargo, Cellular Receptors, drug delivery

Introduction

Exosomes, nanosized membranous vesicles secreted by cells, play crucial roles in intercellular communication. Their ability to carry various biomolecules, including proteins, lipids, and nucleic acids, makes them attractive candidates for drug delivery.[1]

Biogenesis and Composition of Exosomes

Biogenesis of Exosomes

Exosomes originate from the endocytic pathway, specifically through the inward budding of endosomal membranes to form multivesicular bodies (MVBs). The process begins when early endosomes mature into late endosomes, eventually developing into MVBs containing numerous intraluminal vesicles (ILVs). These ILVs are the precursors of exosomes. The fusion of MVBs with the cell membrane results in the release of exosomes into the extracellular space, marking their journey as intercellular messengers.

Several molecular mechanisms govern exosome biogenesis, involving proteins such as ESCRT (endosomal sorting complex required for transport), which orchestrate the sorting and packaging of cargo into ILVs. ESCRT-independent pathways, including lipid raft-mediated sorting, also contribute to the formation of exosomes. Understanding these intricate mechanisms is crucial for manipulating exosomes for drug delivery purposes.[2]Composition of Exosomes

Exosomes boast a diverse and dynamic cargo, reflecting their cellular origin and functional roles. The composition of exosomes is multifaceted, comprising proteins, lipids, nucleic acids, and other bioactive molecules.

Proteins

Exosomes are enriched with various proteins that participate in intercellular signaling. Tetraspanins (CD9, CD63, CD81), Alix, TSG101, and heat shock proteins (HSP70, HSP90) are commonly found in exosomes and are often used as markers for their isolation and characterization. Additionally, specific cell-type markers may be present, reflecting the cellular origin of the exosomes.[3]

Lipids

Lipids play a critical role in maintaining the structural integrity of exosomes. The lipid bilayer membrane of exosomes contains cholesterol, sphingomyelin, phosphatidylserine, and various other lipids. The lipid composition influences the stability and function of exosomes, making them suitable carriers for hydrophobic drugs.

Nucleic Acids

Exosomes encapsulate a diverse range of nucleic acids, including messenger RNA (mRNA), microRNA (miRNA), and other non-coding RNAs. These nucleic acids are protected from degradation, and upon transfer to recipient cells, they can modulate gene expression and cellular functions.

Other Bioactive Molecules

Besides proteins, lipids, and nucleic acids, exosomes may carry enzymes, growth factors, and signaling molecules. The cargo composition is influenced by the physiological state of the cell, and it can be selectively loaded, reflecting the specificity of exosomal cargo packaging mechanisms.

Table 1.Presenting the components and description of composition of exosome[3,4]

Component	Description
Proteins	Tetraspanins (CD9, CD63, CD81), Alix, TSG101, HSP70, HSP90, and cell-specific markers.
Lipids	Cholesterol, sphingomyelin, phosphatidylserine, and various, other lipids in the lipid bilayer membrane.
Nucleic Acids	Messenger RNA (mRNA), microRNA (miRNA), non-coding RNAs, and other genetic material.
Enzymes	Various enzymes involved in cellular processes.
Glycoproteins	Surface glycoproteins influencing interactions with target cells.
Cytokines	Signaling molecules involved in intercellular communication.
Growth Factors	Proteins promoting cell growth, differentiation, and repair.
Other Bioactive molecules	Signaling molecules, antioxidants, and other functional molecules that contribute to the cargo diversity.
Cellular Receptors	Proteins that facilitate the uptake of exosomes by target cells
Exosomal RNA	RNA molecules, including mRNA, miRNA, and other non-coding RNAs.

Engineering Exosomes for Drug Loading

As the spotlight on exosomes intensifies as potential drug delivery vehicles, researchers are directing their focus towards engineering strategies that enhance their drug-loading capacities. This section delves into the innovative approaches and methodologies used to load therapeutic cargo into exosomes, opening new avenues for precision medicine and targeted drug delivery.

Passive Loading

Passive loading involves incubating exosomes with drugs, allowing the cargo to diffuse into the vesicles spontaneously. This straightforward method is effective for hydrophobic compounds that can readily permeate the lipid bilayer of exosomes. Passive loading, although simple, is limited by its dependency on the physicochemical properties of the drug, and its efficiency can vary across different compounds.[5]

Active Loading

In contrast, active loading methods involve manipulating exosomes to actively engulf or encapsulate therapeutic agents. Electroporation, a widely employed technique, employs electric pulses to create transient pores in the exosomal membrane, facilitating the entry of drugs. This method is versatile and can accommodate a broad range of cargo, including small molecules, nucleic acids, and proteins. However, concerns about potential alterations to exosome integrity and cargo leakage persist.

Endogenous Modification of Parent Cells

An intriguing approach involves engineering the parent cells to produce drug-loaded exosomes naturally. This can be achieved through genetic modification or induction of specific cellular pathways. For instance, overexpressing a desired therapeutic protein or RNA within the parent cells can lead to its encapsulation into exosomes during their biogenesis. This method allows for sustained production of drug-loaded exosomes, presenting a promising avenue for long-term therapeutic interventions.

Surface Modification

To enhance the targeting specificity of exosomes, surface modification techniques are being explored. Conjugating exosomes with ligands or peptides that recognize specific receptors on target cells can improve their homing capabilities. This approach aims to increase the precision of drug delivery, reducing off-target effects and enhancing the overall therapeutic efficacy of exosome-loaded drugs.

Challenges and Strategies

Engineering exosomes for drug loading is not without challenges. Maintaining the structural integrity of exosomes, ensuring efficient cargo loading, and minimizing potential immunogenicity are among the hurdles researchers face. To address these challenges, strategies such as optimizing loading conditions, refining purification methods, and conducting comprehensive characterization studies are being employed.[6]

Targeting Strategies

The success of exosome-mediated drug delivery relies significantly on the ability to precisely target specific cells or tissues. This section explores the diverse targeting

strategies employed to enhance the homing capabilities of exosomes, ensuring that therapeutic cargo reaches its intended destination with accuracy and efficiency.

Natural Targeting Properties of Exosomes

Exosomes inherently possess a degree of targeting specificity owing to the presence of surface proteins and ligands derived from their parent cells. Tetraspanins, integrins, and other membrane proteins play crucial roles in determining the natural tropism of exosomes. Understanding and leveraging these natural targeting properties form the foundation for developing more sophisticated strategies.

Surface Modification for Enhanced Targeting

To augment the targeting capabilities of exosomes, researchers employ surface modification techniques. This involves the introduction of ligands, peptides, or antibodies onto the exosome surface that can specifically recognize and bind to receptors on target cells. The choice of ligands depends on the intended therapeutic application, and careful selection ensures greater precision in drug delivery.[7]

Genetic Engineering of Exosome-Producing Cells:

A cutting-edge approach involves modifying the parent cells to produce exosomes with enhanced targeting abilities. By introducing specific genes into the cells, researchers can influence the composition of exosomes and impart them with targeting ligands. This genetic engineering approach allows for the customization of exosomes to meet the unique requirements of different therapeutic interventions.

Exosome Mimetics

Beyond natural exosomes, researchers are exploring the development of synthetic exosome mimetics. These nanoparticles are designed to replicate the structure and function of exosomes, offering a platform for controlled drug delivery. By incorporating targeting moieties onto the surface of these mimetics, researchers aim to achieve a high degree of specificity in directing therapeutic cargo to designated cells or tissues.

Environment-Responsive Targeting

Innovative strategies involve making exosomes responsive to the microenvironment of the target tissue. By incorporating stimuli-responsive elements into the exosome membrane, such as pH-sensitive polymers, researchers can design exosomes that selectively release their cargo in response to specific physiological conditions. This responsive targeting approach enhances precision and minimizes off-target effects.

Combination Strategies

To maximize the effectiveness of targeting, researchers are exploring combination strategies. This involves integrating multiple targeting moieties or employing a combination of surface modification and genetic engineering approaches. Such strategies capitalize on synergistic effects to enhance the specificity and efficiency of exosome-mediated drug delivery.[5,6]

Challenges and Considerations

While targeting strategies show great promise, challenges remain. Factors such as systemic clearance, off-target effects, and potential immunogenicity necessitate careful consideration in the design and application of targeting strategies. Addressing these challenges is crucial for advancing the clinical translation of exosome-mediated drug delivery.

Immunogenicity and Biodistribution

As exosomes surge into the spotlight as potential drug delivery vehicles, understanding their immunogenicity and biodistribution becomes paramount for successful clinical translation. This section delves into the intricate interplay between exosomes and the immune system, as well as the journey these nanocarriers undertake within the body, shedding light on the challenges and considerations essential for advancing the field of exosome-mediated drug delivery.

Immunogenicity of Exosomes

Exosomes, being derived from cells, inherently carry molecular markers that may trigger an immune response. The potential immunogenicity of exosomes raises critical concerns, as immune reactions could compromise their therapeutic efficacy and safety. Studies are exploring the immunological responses triggered by exosomes, investigating ways to mitigate unwanted reactions through modifications in exosome composition or surface engineering.[9]

Strategies to Mitigate Immunogenicity

Researchers are actively developing strategies to minimize the immunogenicity of exosomes. Techniques include altering the composition of exosomes to reduce the expression of immunogenic proteins, using immunomodulatory drugs during exosome production, or employing cell lines with low immunogenicity for exosome isolation. These approaches aim to enhance the biocompatibility of exosomes and improve their acceptance by the host immune system.

Biodistribution of Exosomes

Understanding the biodistribution of exosomes is crucial for predicting their fate within the body. Upon administration, exosomes navigate a complex journey, encountering barriers such as the reticuloendothelial system, vascular endothelium, and extracellular matrix. Various factors, including size, surface charge, and surface modifications,

influence the biodistribution of exosomes, impacting their therapeutic effectiveness.[2,3]

Factors Influencing Biodistribution

Size and Surface Charge

The size of exosomes plays a pivotal role in determining their biodistribution. Smaller exosomes may exhibit prolonged circulation times and improved tissue penetration, influencing their distribution to target sites. Additionally, surface charge influences interactions with the vascular endothelium, affecting extravasation and tissue accumulation.

Surface Modifications

Surface modifications, such as the addition of targeting ligands or stealth coatings, can significantly impact the biodistribution of exosomes. These modifications may enhance specific targeting to diseased tissues or extend circulation times, thereby optimizing the therapeutic delivery of cargo.[9]

Technological Advances in Biodistribution Studies

Advancements in imaging technologies, including magnetic resonance imaging (MRI), positron emission tomography (PET), and near-infrared fluorescence (NIRF), have enabled researchers to track the biodistribution of exosomes in real-time. These techniques provide invaluable insights into the pharmacokinetics of exosomes, aiding in the optimization of drug delivery strategies.

Therapeutic Applications

As the field of exosome-mediated drug delivery rapidly advances, researchers are exploring a diverse array of therapeutic applications for these nanocarriers. This section provides an in-depth exploration of the promising therapeutic avenues where exosomes exhibit significant potential, ranging from cancer therapy to regenerative medicine.

Cancer Therapy

Exosome-mediated drug delivery has garnered significant attention in the realm of cancer therapy. These nanocarriers offer a unique advantage in delivering chemotherapeutic agents directly to cancer cells, minimizing systemic toxicity. Additionally, the natural targeting ability of exosomes can be harnessed to guide therapeutic cargo specifically to tumor sites, enhancing treatment efficacy while reducing side effects. Beyond conventional chemotherapy, exosomes are being explored for the targeted delivery of gene therapies, immunotherapies, and combination therapies against various forms of cancer.[10]

Neurodegenerative Disorders

The blood-brain barrier poses a formidable challenge in the treatment of neurodegenerative disorders. Exosomes, with their ability to traverse biological barriers and deliver cargo to the central nervous system, hold promise for treating conditions such as Alzheimer's, Parkinson's, and Huntington's diseases. Researchers are investigating the potential of exosomes to deliver neuroprotective agents, small molecules, or nucleic acids, aiming to modulate disease progression or promote neural regeneration.

Inflammatory and Autoimmune Diseases

Exosomes play a role in immune regulation and are being explored as therapeutic agents in inflammatory and autoimmune diseases. These nanocarriers can be engineered to carry anti-inflammatory agents or immunomodulatory molecules, providing a targeted approach to dampen immune responses. By leveraging the natural intercellular communication facilitated by exosomes, researchers aim to modulate immune responses and alleviate symptoms associated with conditions like rheumatoid arthritis, multiple sclerosis, and inflammatory bowel diseases.[11]

Cardiovascular Diseases

Cardiovascular diseases, including ischemic heart disease and heart failure, pose significant health challenges worldwide. Exosomes offer a novel avenue for delivering therapeutic cargo to the heart, promoting tissue repair and regeneration. Studies are investigating the potential of exosomes in delivering growth factors, microRNAs, or other regenerative agents to enhance cardiac function and mitigate the effects of cardiovascular diseases.

Regenerative Medicine

Exosomes hold immense potential in regenerative medicine by promoting tissue repair and regeneration. Researchers are exploring their use in promoting wound healing, bone regeneration, and tissue engineering. Exosomes derived from stem cells, in particular, exhibit regenerative properties and are being investigated for their ability to enhance tissue repair in various clinical context0.[12]

Metabolic Disorders

Metabolic disorders such as diabetes and obesity present complex challenges in terms of treatment. Exosomes are being explored for their role in delivering therapeutic agents that can modulate metabolic pathways or enhance insulin sensitivity. By exploiting the natural communication between cells, exosome-mediated drug delivery holds promise for addressing the underlying mechanisms of metabolic disorders.

Infectious Diseases

Exosomes are also emerging as potential tools in the treatment of infectious diseases. Researchers are exploring their use in delivering antiviral agents, antibodies, or RNA-based therapeutics to combat viral infections. Additionally, the immunomodulatory properties of exosomes are being investigated to enhance the host immune response against bacterial and fungal infections.

Table 2.Showing the therapeutic application of Exosomes as Drug Delivery Vehicles[13,14]

Therapeutic Application	Description
Cancer Therapy	Targeted delivery of chemotherapeutic agents, gene therapies, and immunotherapies to cancer cells, minimizing systemic toxicity.
Neurodegenerative Disorders	Potential treatment for conditions like Alzheimer's, Parkinson's, and Huntington's diseases, delivering neuroprotective agents and promoting neural regeneration.
Inflammatory and Autoimmune Diseases	Targeted delivery of anti-inflammatory agents or immunomodulatory molecules to modulate immune responses in diseases such as rheumatoid arthritis and multiple sclerosis.
Cardiovascular Diseases	Delivery of therapeutic agents to the heart to enhance tissue repair and regeneration for conditions like ischemic heart disease and heart failure.
Regenerative Medicine	Promotion of tissue repair and regeneration, with applications in wound healing, bone regeneration, and tissue engineering.
Metabolic Disorders	Targeted delivery of agents modulating metabolic pathways for conditions like diabetes and obesity.
Infectious Diseases	Potential treatment for viral infections through the delivery of antiviral agents, antibodies, or RNA-based therapeutics.
Genetic Disorders	Delivery of gene therapies to address genetic abnormalities and disorders.
Drug Delivery to CNS	Crossing the blood-brain barrier for the treatment of neurological disorders.
Tissue-specific Therapies	Targeted delivery to specific tissues or organs for personalized medicine.
Combination Therapies	Utilizing exosomes to deliver combinations of drugs for synergistic therapeutic effects.
Immunotherapy Enhancement	Augmentation of immunotherapies by delivering immunomodulatory agents.
Pain Management	Targeted delivery of analgesic agents for localized pain relief.

Challenges and Future Perspectives

Challenges and future perspectives in harnessing exosomes as drug delivery vehicles underscore the dynamic nature of this burgeoning field. Despite their immense potential, several challenges persist, ranging from the reproducibility of exosome isolation methods to concerns regarding immunogenicity and achieving consistent drug-loading efficiencies. [15] The heterogeneity in exosome populations derived from different cell sources further complicates standardization. Addressing these challenges requires a multifaceted approach, involving advancements in isolation techniques, thorough characterization protocols, and innovative strategies for minimizing immunogenic responses. Additionally, the scalability of exosome production remains a hurdle for clinical translation. Looking ahead, the future of exosome-based drug delivery holds great promise.[16] Advancements in bioengineering and nanotechnology will likely contribute to overcoming current challenges. Furthermore, the integration of artificial intelligence and machine learning in designing tailored exosome formulations and predicting their behavior in vivo represents a frontier for optimizing therapeutic outcomes. As research continues to unravel the intricacies of exosome biology, the potential for these extracellular vesicles to revolutionize drug delivery and personalized medicine appears increasingly within reach.[17]

Conclusion

In conclusion, the journey of harnessing exosomes as drug delivery vehicles presents a compelling narrative of challenges confronted and the promise of groundbreaking advancements. The intricacies of exosome isolation, variability in populations, and concerns related to immunogenicity demand meticulous attention for the successful translation of exosome-mediated drug delivery into clinical applications. The pursuit of standardized isolation techniques, innovative drug-loading strategies,

and a deeper understanding of immunogenic responses remains imperative. Despite these challenges, the future holds exciting prospects. The convergence of cutting-edge technologies, such as bioengineering, nanotechnology, and artificial intelligence, is poised to reshape the landscape. As these challenges are systematically addressed, exosomes stand poised to redefine drug delivery paradigms, offering precision and efficacy in therapeutic interventions across a spectrum of diseases. The journey ahead is dynamic, propelled by the relentless pursuit of knowledge, innovative solutions, and a vision where exosomes emerge not just as carriers of drugs but as transformative agents in the realm of personalized medicine.

References

1. Théry C, Zitvogel L, & Amigorena, S. (2002). Exosomes: composition, biogenesis and function. Nature Reviews Immunology, 2(8), 569-579.
2. Vader P, Mol EA, Pasterkamp G, Schiffelers RM. Extracellular vesicles for drug delivery. Advanced Drug Delivery Reviews 2016; 106: 148-156.
3. EL Andaloussi, S., Mäger, I., Breakefield, X. O., & Wood, M. J. (2013). Extracellular vesicles: biology and emerging therapeutic opportunities. Nature Reviews Drug Discovery, 12(5), 347-357.
4. Alvarez-Erviti, L., Seow, Y., Yin, H., Betts, C., Lakhal, S., & Wood, M. J. (2011). Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nature Biotechnology, 29(4), 341-345.
5. Kamerkar, S., LeBleu, V. S., Sugimoto, H., Yang, S., Ruivo, C. F., Melo, S. A., ... & Kalluri, R. (2017). Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature, 546(7659), 498-503.
6. Lamichhane, T. N., Raiker, R. S., Jay, S. M. (2015). Exogenous DNA loading into extracellular vesicles via electroporation is size-dependent and enables limited gene delivery. Molecular Pharmaceutics, 12(10), 3650-3657.
7. Lai, R. C., Arslan, F., Lee, M. M., Sze, N. S., Choo, A., Chen, T. S., ... & Lim, S. K. (2010). Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Research, 4(3), 214-222.
8. Tian, Y., Li, S., Song, J., Ji, T., Zhu, M., Anderson, G. J., & Nie, G. (2014). A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials, 35(7), 2383-2390.
9. Kim, M. S., Haney, M. J., Zhao, Y., Yuan, D., Deygen, I., Klyachko, N. L., & Batrakova, E. V. (2016). Engineering macrophage-derived exosomes for targeted paclitaxel delivery to pulmonary metastases: in vitro and in vivo evaluations. Nanomedicine: Nanotechnology, Biology and Medicine, 14(1), 195-204.
10. Jang, S. C., Kim, O. Y., Yoon, C. M., Choi, D. S., Roh, T. Y., Park, J., ... & Kim, Y. K. (2013). Bioinspired exosome-mimetic nanovesicles for targeted delivery of chemotherapeutics to malignant tumors. ACS Nano, 7(9), 7698-7710.
11. Yang, Y., Hong, Y., Nam, G. H., Chung, J. H., Koh, E., Kim, I. S. (2018). Virus-mimetic fusogenic exosomes for direct delivery of integral membrane proteins to target cell membranes. Advanced Materials, 30(40), 1804602.
12. Haney, M. J., Klyachko, N. L., Zhao, Y., Gupta, R., Plotnikova, E. G., He, Z., ... & Batrakova, E. V. (2015). Exosomes as drug delivery vehicles for Parkinson's disease therapy. Journal of Controlled Release, 207, 18-30.
13. Alvarez-Erviti, L., Seow, Y. Q., Yin, H., Betts, C., Lakhal, S., & Wood, M. J. (2011). Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nature Biotechnology, 29(4), 341.
14. Zhuang, X., Xiang, X., Grizzle, W., Sun, D., Zhang, S., Axtell, R. C., ... & Zhang, H. G. (2011). Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain. Molecular Therapy, 19(10), 1769-1779.
15. Qi, H., Liu, C., Long, L., Ren, Y., Zhang, S., Chang, X., ... & Qian, X. (2016). Blood exosomes endowed with magnetic and targeting properties for cancer therapy. ACS Nano, 10(3), 3323-3333.
16. Li, J., Lee, Y., Johansson, H. J., Mäger, I., Vader, P., Nordin, J. Z., ... & Valadi, H. (2015). Serum-free culture alters the quantity and protein composition of neuroblastoma-derived extracellular vesicles. Journal of Extracellular Vesicles, 4(1), 26883.
17. Wahlgren, J., De L Karlson, T., Brisslert, M., Vaziri Sani, F., Telemo, E., & Sunnerhagen, P. (2012). Plasma exosomes can deliver exogenous short interfering RNA to monocytes and lymphocytes. Nucleic Acids Research, 40(17), e130.